Cite
Moretto R, Rossini D, Conca V, et al. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. Br J Cancer. 2021;125(6):839-845doi: 10.1038/s41416-021-01483-x.
Moretto, R., Rossini, D., Conca, V., Lonardi, S., Rasola, C., Antoniotti, C., Santini, D., Marmorino, F., Tomasello, G., Borelli, B., Caponnetto, S., Zucchelli, G., Zaniboni, A., Ambrosini, M., Buonadonna, A., Fanchini, L., Cupini, S., Masi, G., Falcone, A., & Cremolini, C. (2021). CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. British journal of cancer, 125(6), 839-845. https://doi.org/10.1038/s41416-021-01483-x
Moretto, Roberto, et al. "CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies." British journal of cancer vol. 125,6 (2021): 839-845. doi: https://doi.org/10.1038/s41416-021-01483-x
Moretto R, Rossini D, Conca V, Lonardi S, Rasola C, Antoniotti C, Santini D, Marmorino F, Tomasello G, Borelli B, Caponnetto S, Zucchelli G, Zaniboni A, Ambrosini M, Buonadonna A, Fanchini L, Cupini S, Masi G, Falcone A, Cremolini C. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. Br J Cancer. 2021 Sep;125(6):839-845. doi: 10.1038/s41416-021-01483-x. Epub 2021 Jul 12. PMID: 34253871; PMCID: PMC8437964.
Copy
Download .nbib